• Aaron R Ducoffe, Andrew York, Dale J Hu, Deborah Perfetto, and Robert D Kerns.
• *Previously with Office of Disease Prevention and Health Promotion (ODPHP), US Department of Health and Human Services, Washington, DC; Currently with MedStar Georgetown University Hospital, Department of Radiology, Washington, DC.
• Pain Med. 2016 Dec 1; 17 (12): 229123042291-2304.

AbstractAdverse drug events (ADEs) have been highlighted as a major patient safety and public health challenge by the National Action Plan for Adverse Drug Event Prevention (ADE Action Plan), which was released by the Office of Disease Prevention and Health Promotion (ODPHP) in August 2014. The ADE Action Plan focuses on surveillance, evidence-based prevention, incentives, and oversights, additional research needs as well as possible measures and metrics to track progress of ADE prevention within three drug classes: anticoagulants, diabetes agents, and opioids.Objectives and Recommendations. With outpatient opioid prescriptions being a great concern among many healthcare providers, this article focuses on recommendations from the ADE Action Plan to help guide safer opioid use in healthcare delivery settings. Its aim is to discuss current federal methods in place to prevent opioid ADEs while also providing evidence to encourage providers and hospitals to innovate new systems and practices to increase prevention.Published by Oxford University Press on behalf of the American Academy of Pain Medicine. 2016. This work is written by US Government employees and is in the public domain in the US.

15 keywords...

hide…